Table 2.
Countries with moderate endemic rates (2–10 cases/100,000 population per year)
| Country | Year | Incidence/100,000 population | Predominant serogroup | Source | Comments |
|---|---|---|---|---|---|
|
African Region |
|
|
|
|
|
|
South Africa |
2000–2005 |
0.8–4 |
B in Western Cape |
[22] |
|
|
Eastern Mediterranean Region | |||||
|
No country in this region is in the moderate rate category | |||||
|
European Region | |||||
|
Belgium |
1999–2010 |
2.9 (pre-vaccine) |
B, C |
[23,24] |
A conjugate vaccine for group C was introduced in 2002 |
| 0.89 (post-vaccine) | |||||
|
Denmark |
1999–2010 |
1.19–3.5 |
B |
[23,24] |
|
|
Greece |
|
0.49–2.0 |
C |
[23,24] |
A conjugate vaccine for group C introduced in 2001 in pediatric population[25] |
|
Ireland |
|
14.3 (pre-vaccine) |
B, C |
[23,24] |
A conjugate vaccine for group C was |
| |
|
2.19 (post-vaccine) |
|
|
introduced in 2001 |
|
Iceland |
|
7.6 (pre-vaccine) |
B, C |
[23,24] |
A conjugate vaccine for group C was |
| |
|
0.6 (post-vaccine) |
|
|
introduced in 2002 |
|
Lithuania |
2004–2010 |
1.4–2.6 |
* |
[23,24] |
|
|
Luxemburg |
1999–2010 |
0.2–5.68 |
* |
[23,24] |
|
|
Malta |
1994–2007 |
0.8–8.9 |
B, C |
[26] |
2 peaks in 2000 and 2006 |
|
Netherland |
1999–2010 |
3.6 (pre-vaccine) |
B, C |
[23,24] |
A conjugate vaccine for group C was introduced in 2002 |
| 0.86 (post-vaccine) | |||||
|
Norway |
1992–2010 |
0.8–4.6 |
B |
[23,27] |
|
|
Portugal |
2000–2010 |
0.74–3.0 |
B, C |
[23,28] |
|
|
Spain |
1999–2010 |
3.52 (pre-vaccine) |
B, C |
[23,24] |
A conjugate vaccine for group C introduced in 2001 |
| 0.88 (post vaccine) | |||||
|
Switzerland |
1999–2004 |
1.16–2.36 |
C |
[24] |
A conjugate vaccine for group C introduced in 2005 |
|
Turkey |
1997–2005 |
0.3–2.2 |
* |
[28] |
|
|
United Kingdom |
1999–2010 |
5.4 (pre-vaccine) |
B, C |
[23,24] |
A conjugate vaccine for group C introduced in 1999 |
| 1.63 (post vaccine) | |||||
|
Region of the Americas | |||||
|
Brazil |
1998–2006 |
1–4.5 |
B, now C |
[19] |
A combined vaccine against serogroup B (OMV) and C (polysaccharide) was introduced in 1990 |
|
Cuba |
1998–2003 |
3.4-8.5 (pre-vaccine) |
B |
[29] |
A combined vaccine against serogroup B (OMV) and C (polysaccharide) was introduced in 1987 |
| <1 (post-vaccine) | |||||
|
South-East Asia Region | |||||
|
No country in this region is in the moderate rate category | |||||
|
Western Pacific Region | |||||
| Australia | 1995–2006 | 3.5–7.9 (pre-vaccine) |
B | [30] | A conjugate vaccine for Serogroup C was introduced in 2003 |
| 1.4 (post-vaccine) | |||||
* Data not available.